Investment
Features
FeesSafety
Academy
More
Pluang+

Compare EOG Resources Inc (EOG) vs Viatris Inc (VTRS) Price & Performance

EOG Resources IncTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

EOG Resources Inc vs Viatris Inc — how do they compare? EOG Resources Inc trades at $148.8 (market cap $77.90B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: EOG Resources Inc is far larger — about 3.9× Viatris Inc's market cap, and Viatris Inc is more actively traded (14,109,977 versus 2,930,386). Which is the better fit depends on your goals — on Pluang, investors hold EOG Resources Inc for 59 Days and Viatris Inc for 57 Days on average.

EOGVTRS
Market Cap
$77.90B$20.03B
Volume
2,930,38614,109,977
Sector
EnergyHealth
52-Week High
$153.74$18.27
52-Week Low
$101.78$9.74
Typical Hold Time
59 Days57 Days
Enterprise Value
$81.24B$32.15B
Dividend Yield
2.75%2.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

EOG Resources Inc

EOG Resources trades at $148.16, up 2.74% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with 25.81% net income margin and consistent earnings beats, though revenue declined to $22.58B in 2025. Recent CFO transition and upcoming Q3 earnings on November 6, 2026 are key developments. Technical indicators show the stock trading near pivot point resistance at $148 with RSI suggesting potential overbought conditions.

EOG presents a compelling value opportunity with attractive valuation multiples (P/E 11.56, EV/EBITDA 5.84) and strong analyst support (59% buy rating, $164.77 target). Risks include oil price volatility and recent insider selling. The company's disciplined capital allocation and 5% oil volume growth guidance support long-term upside potential despite near-term revenue pressures.

Viatris Inc

Viatris (VTRS) trades at $17.64, up 0.86% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.69 exceeding expectations. Revenue for 2025 was $14.3 billion, though net income was negative. Analyst consensus is a 'Buy' with a $22.17 price target, representing 26% upside. Recent news highlights include a new drug approval in Japan and recognition as a top employer.

The outlook for VTRS is cautiously optimistic, supported by earnings beats and a positive analyst stance, but tempered by negative profit margins and high debt. Key opportunities include operational cash flow strength and pipeline progress, while risks involve sustained profitability challenges and competitive pressures in the generics market.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

EOG
13% Buy87% Sell
Avg holding period · 59 Days
VTRS
100% Buy0% Sell
Avg holding period · 57 Days

Top news

Latest headlines on both assets

About EOG Resources Inc

EOG Resources is an oil and gas producer with acreage in several U.S. shale plays, including the Permian Basin, the Eagle Ford, and the Bakken. At the end of 2021, it reported net proved reserves of 3.7 billion barrels of oil equivalent. Net production averaged 829 thousand barrels of oil equivalent per day in 2021 at a ratio of 72% oil and natural gas liquids and 28% natural gas.

Read more on EOG →

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS →